Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate to Provide Symptomatic Relief of Osteoarthritis of the Knee
Sponsor: Anika Therapeutics, Inc.
Listed as NCT00653432, this NA trial focuses on Osteoarthritis and remains completed. Sponsored by Anika Therapeutics, Inc., it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Aug 2023 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Aug 2023 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed NA
-
Jun 2018 — Oct 2020 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anika Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .